World stem cell leaders will converge on Promega’s BioPharmaceutical
Technology Center in Fitchburg, Wisconsin, on April 30 for the 9th
Annual Wisconsin Stem Cell Symposium: From Stem Cells to Blood.
Coordinated by the nonprofit BioPharmaceutical Technology Center Institute, the University of Wisconsin-Madison Stem Cell and Regenerative Medicine Center
and the UW-Madison Blood Research Program, this year’s symposium is
focused on how the stem cells that give rise to blood develop and
It will also look at the diversity of insights stem cell
studies have provided other fields.
Highlighted topics include genesis and regulation of progenitor cells
and hematopoietic stem cells, stem cell genomes/epigenomes, stem cell
microenvironment, and tumor initiating
Image via Wikipedia
Discovery sheds new light on the process of stem cell generation, and will help promote safer stem-cell based studies and future clinical trials.
Dr. Andras Nagy’s laboratory at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Timo Otonkoski’s laboratory at Biomedicum Stem Cell Center (University of Helsinki), as well as collaborators in Europe and Canada have identified genetic abnormalities associated with reprogramming adult cells to induced pluripotent stem (iPS) cells. The findings give researchers new insights into the reprogramming process, and will help make future applications of stem cell creation and subsequent use safer.
Stanford University’s Faculty Senate today approved the creation of what officials believe is the first PhD program devoted solely to stem cell science in the nation and, perhaps, the world. The new doctoral program in stem cell biology and regenerative medicine is also the first interdisciplinary doctoral program created by the School of Medicine in recent years.
School officials say the fact that the university is taking the rare step of creating a new doctoral program acknowledges the growing importance of stem cell research in the realm of biomedical science. The senate’s initial approval
Image via Wikipedia
A new research has suggested that cardiac stem cells – even in elderly and sick patients – could generate new heart muscle and vessel tissue and be used to treat heart failure.
Scientists surgically removed tissue from the muscular wall of the heart’s chambers in 21 patients.
They then isolated and multiplied the cardiac stem cells (CSCs) found there.
Most of the patients had ischemic cardiomyopathy (enlarged and weakened muscle due to coronary artery disease). Eleven also had diabetes. The average age of patients was about 65.
“Regardless of the gender or age of the patient, or of diabetes, we were
Academic institutions are in a much better position than pharmaceutical companies to make the best decisions about which therapies deserve further development. That was the underlying message from a pair of Stanford researchers at a panel on stem cell science at last weekend’s Association of Health Care Journalism 2015 conference.
“There’s an inherent flaw in our system,” said Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. “Companies are driven by the desire for profits rather than the desire to find the best therapy, and they often give up on discoveries too early.”